APA 6th Edition

Kehler, T. (2011). The safety of rituximab (Mabthera®) treatment in rheumatoid arthritis patients. Reumatizam, 58 (2), 189-189. Preuzeto s https://hrcak.srce.hr/124473

---

MLA 8th Edition

Kehler, Tatjana. "The safety of rituximab (Mabthera®) treatment in rheumatoid arthritis patients." Reumatizam, vol. 58, br. 2, 2011, str. 189-189. https://hrcak.srce.hr/124473. Citirano 17.11.2024.

---

Chicago 17th Edition

Kehler, Tatjana. "The safety of rituximab (Mabthera®) treatment in rheumatoid arthritis patients." Reumatizam 58, br. 2 (2011): 189-189. https://hrcak.srce.hr/124473

---

Harvard

Kehler, T. (2011). 'The safety of rituximab (Mabthera®) treatment in rheumatoid arthritis patients', Reumatizam, 58(2), str. 189-189. Preuzeto s: https://hrcak.srce.hr/124473 (Datum pristupa: 17.11.2024.)

---

Vancouver

Kehler T. The safety of rituximab (Mabthera®) treatment in rheumatoid arthritis patients. Reumatizam [Internet]. 2011 [pristupljeno 17.11.2024.];58(2):189-189. Dostupno na: https://hrcak.srce.hr/124473

---

IEEE

T. Kehler, "The safety of rituximab (Mabthera®) treatment in rheumatoid arthritis patients", Reumatizam, vol.58, br. 2, str. 189-189, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/124473. [Citirano: 17.11.2024.]